MAP2K7 and breast cancer: To verify whether GHR is associated with breast cancer progression by modulating the BRAF/MEK/ERK signaling pathway, we evaluated the roles of GHR silencing in the expression of p‐BRAF, p‐MEK and p‐ERK.